Lodine

• Nonsteroidal Antiinflammatory Agents (NSAIDs)
• ATC:M01AB08

• Etodolac [Usan:Ban:Inn]
• Etodolacetodolic acid
• Etodolaco [Inn-Spanish]
• Etodolacum [Inn-Latin]
• Etodolic Acid
• Lodine
• Lodine XL
• Ultradol

No information avaliable

C₁₇H₂₁NO₃

http://www.rxlist.com/cgi/generic/etodolac.htm

Lodine FDA

CA Demerson et al., Patente de EE.UU.. 3,939,178 (1976)

287.354 g/mol

145-148 ^oC

16 mg / L

Solid

No information avaliable

Tablet, Tablet (de liberación prolongada)

Para el uso a corto y largo plazo en la gestión de los signos y síntomas de la osteoartritis y la artritis reumatoide, así como para el tratamiento del dolor.

Etodolac, un agente antiinflamatorio con propiedades analgésicas y antipiréticas, se utiliza para tratar la osteoartritis y el control del dolor agudo.

Con base en estudios de balance de masa, la disponibilidad sistémica de etodolac de cualquiera de los comprimidos o cápsulas, es al menos el 80%.

Los síntomas de sobredosis incluyen letargo, somnolencia, náuseas, vómitos y dolor epigástrico.

Lodine, like other drugs of its class, can cause discomfort and, rarely, more serious side effects, such as gastrointestinal bleeding, which may result in hospitalization and even fatal outcomes. Although serious GI tract ulcerations and bleeding can occur without warning symptoms, patients should be alert for the signs and symptoms of ulcerations and bleeding, and should ask for medical advice when observing any indicative sign or symptom. Patients should be informed of the importance of this follow-up Effects Risk of GI Ulceration, Bleeding, and Perforation).

Patients on Lodine (etodolac capsules and tablets) should report to their physicians signs or symptoms of gastrointestinal ulceration or bleeding, blurred vision or other eye symptoms, skin rash, weight gain, or edema.

Patients should also be instructed to seek medical emergency help in case of an occurrence of anaphylactoid reactions.

Humanos y otros mamíferos